U.S. stocks higher, Nasdaq Composite up 1%. Tango Therapeutics (TNGX) shares up 34.1% on positive trial data. Other big gainers include ENHA, JLHL, ABAT, BTGO, GLXY, CLYM, SOC, SRAD, AIAI, ALOY, and GENI.

Tango Therapeutics reports 90% 6-month PFS in pancreatic cancer trial. Read about the vopimetostat combo driving TNGX stock up.

U.S. stocks higher, Nasdaq Composite up 1%. Tango Therapeutics (TNGX) shares up 34.1% on positive trial data. Other big gainers include ENHA, JLHL, ABAT, BTGO, GLXY, CLYM, SOC,…